A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature

Kabir A Khan; Robert S Kerbel

doi:10.1016/j.ccell.2017.03.009

A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature

Cancer Cell. 2017 Apr 10;31(4):469-471. doi: 10.1016/j.ccell.2017.03.009.

Authors

Kabir A Khan¹, Robert S Kerbel²

Affiliations

¹ Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada. Electronic address: kkhan@sri.utoronto.ca.
² Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.

PMID: 28399405
DOI: 10.1016/j.ccell.2017.03.009

Abstract

In this issue of Cancer Cell, Seaman et al. demonstrate that antibody drug conjugates (ADCs) against CD276 expressed by tumor cells and tumor vasculature have promising anti-tumor activity while showing little toxicity. Importantly, these agents have the potential to target both angiogenic vessels and non-angiogenic vessels co-opted by tumor cells.

Publication types

Comment

MeSH terms

Antibodies*
Cell Line, Tumor*
Humans
Immunoconjugates

Substances

Antibodies
Immunoconjugates